Peregrine Pharma (PPHM) Tops Q4 EPS by 1c

Peregrine Pharma (NASDAQ: PPHM) reported Q4 EPS of ($0.07), $0.01 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $9.31 million versus the consensus estimate of $6.42 million.

For earnings history and earnings-related data on Peregrine Pharma (PPHM) click here.

You May Also Be Interested In

• Nvidia’s AI dominance funds historic $150 billion buyback
• What past S&P 500 drawdowns reveal about today’s market, according to RBC
• IQVIA Holdings (IQV) PT Raised to $329 at Truist Securities